Lucid Capital initiated coverage of Forte Biosciences (FBRX) with a Buy rating and $28 price target entered clinical development for indications which could result in FB-102 growing into a blockbuster drug for multiple indications, the analyst tells investors in a research note. The firm says that while the lead indication celiac disease represents a “relatively modest, but significant market opportunity,” FB-102 could subsequently be developed for diseases representing billion-dollar market potentials.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBRX: